QNRX News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$8.1M

Volume

31.46K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Quoin (QNRX) Q2 Loss Beats EstimatesQuoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.The Motley Fool · Aug 8, 2025

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome TrialsQuoin Pharmaceuticals announced highly positive interim data from its ongoing Netherton Syndrome clinical trials, with the first subject demonstrating marked improvements across all measured endpoints after 12 weeks of treatment with the company's QRX003 topical lotion. The company is optimistic about the therapy's potential to effectively treat this rare and debilitating skin disease.GlobeNewswire Inc. · Jan 7, 2025

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National ConferenceASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.GlobeNewswire Inc. · Jun 25, 2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), IrelandAgreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseasesGlobeNewswire Inc. · Jun 12, 2024

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.GlobeNewswire Inc. · May 2, 2024

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To KnowMaxim Group has decided to maintain its Buy rating of Quoin Pharmaceuticals (NASDAQ:QNRX) and lower its price target from $15.00 to $4.00. Shares of Quoin Pharmaceuticals are trading up 2.0% over the last 24 hours, at $1.02 per share. A move to $4.00 would account for a 292.16% increase from the current share price. About Quoin Pharmaceuticals Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of ...Full story available on Benzinga.comBenzinga · Mar 15, 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsCompany reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpointsGlobeNewswire Inc. · Mar 13, 2024

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.GlobeNewswire Inc. · Mar 7, 2024

Crude Oil Down 1%; Dave Shares Jump After Q4 ResultsU.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500 also fell, dropping, 1.05% to 5,076.98. Check This Out: Jim Cramer: This Semiconductor Company Is 'Too Late To Auto,' But Super Micro Is 'Too Hot' Leading and Lagging Sectors Energy shares rose by 1.3% on Tuesday. In trading on Tuesday, information technology shares fell by 2.2%. Top Headline Consolidated Communications Holdings Inc (NASDAQ: CNSL) posted a narrower-than-expected loss for its fourth quarter. The company reported a fourth-quarter fiscal 2023 revenue decline of 7.0% year-on-year to $275.2 million, missing the analyst consensus of $276.9 million. Adjusted loss of 26 cents beat the analyst consensus loss of 36 cents. Equities Trading UP Dave Inc. (NASDAQ: DAVE) shares shot up 51% to $32.99 after the company reported a year-over-year increase in fourth-quarter revenue results. Shares of Airship AI Holdings, Inc. (NASDAQ: AISP) got a boost, surging 87% to $3.08 after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform. Apogee Therapeutics, Inc. (NASDAQ: APGE) shares were also up, gaining 51% ...Benzinga · Mar 5, 2024

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionShares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. Sophia Genetics posted GAAP loss of 37 cents per share, versus market expectations for a loss of 27 cents per share. The company’s quarterly sales came in at $17.05 million, missing estimates of $17.33 million. SOPHiA GENETICS shares tumbled 19% to $4.55 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) climbed 146.3% to $0.1106 after dipping 19% on Monday. Sunshine Biopharma recently announced closing of $10.0 million underwritten public offering. Airship AI Holdings, Inc. (NASDAQ: AISP) climbed 93.3% to $3.16 after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform. Bruush Oral Care Inc. (NASDAQ: BRSH) surged 42.9% to $0.0686. Apogee Therapeutics, Inc. (NASDAQ: APGE) shares jumped 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results. Dave Inc. (NASDAQ: DAVE) gained 39.8% to $30.62 after the company reported a year-over-year increase in fourth-quarter revenue results. CareMax, Inc. (NASDAQ: CMAX) rose 38.1% to $10.65. Enviva Inc. (NYSE: EVA) gained 26.4% to $0.6571. AeroVironment, Inc. (NASDAQ: AVAV) shares surged 24.8% to $163.05 after the company reported better-than-expected results for its fourth quarter. The company said it sees FY24 adjusted earnings of $2.69 to $2.83 per share on revenue of $700 million to $710 million. INNOVATE Corp. (NASDAQ: VATE) rose 24.4% to $0.90. The company reported fourth quarter financial results. Ocean Biomedical, Inc. (NASDAQ: OCEA) climbed 24.3% to $5.07. Paymentus Holdings, Inc. (NYSE: PAY) rose gained 20.3% to $19.67 after the company reported better-than-expected fourth quarter financial results. BeyondSpring Inc. (NASDAQ: BYSI) gained 20.1% to $1.97. bioAffinity Technologies, Inc. (NASDAQ: BIAF) climbed 19.4% to $2.83. bioAffinity Technologies reported accelerating sales growth of CyPath® Lung. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 18.4% to $4.18. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) ...Benzinga · Mar 5, 2024

QNRXQuoin Pharmaceuticals, Ltd. American Depositary Shares

QNRX

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any QNRX yet.

Related Tickers

Earnings

Volume

31.46K

Next Earnings

November 5th